Silexion Announces Promising Pancreatic Cancer Study Results
Silexion Therapeutics (NASDAQ: SLXN) has completed data collection for its first study of SIL-204 in orthotopic pancreatic cancer models....
Jon Napitupulu
Ampligen and Imfinzi in Phase 2 Pancreatic Cancer Trial
AIM ImmunoTech has dosed the first patient in Phase 2 of its Phase 1b/2 clinical trial, DURIPANC, evaluating Ampligen...
Alzamend Neuro Starts Phase 2 Trial of AL001 at Mass General
Alzamend Neuro plans to initiate the first of five Phase II clinical trials for AL001, a novel lithium-delivery system,...
Candel Therapeutics Announces Positive CAN-2409 Trial Data
Candel Therapeutics announced positive final overall survival data from its Phase 2 trial of CAN-2409 in patients with borderline...
PrecivityAD2 Blood Test Certified in UK
C2N Diagnostics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its PrecivityAD2...
LTZ-301: First-in-Class Myeloid Engager Immunotherapy IND Cleared by FDA
LTZ Therapeutics received FDA clearance for its Investigational New Drug (IND) application for LTZ-301. LTZ-301, a first-in-class myeloid engager...
Regeneron db-oto Results Show Hearing Improvement in Children with Genetic Hearing Loss
Regeneron Pharmaceuticals announced updated positive data from its ongoing Phase 1/2 CHORD trial of DB-OTO, a gene therapy for...
EMA and EU-Medicines for All Validate Lenacapavir HIV Prevention Application
Gilead Sciences announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) and EU-Medicines for...
FDA Clears Ruxolitinib Phase 2 Study for Dermatomyositis Treatment
NovelMed Therapeutics has received FDA clearance to initiate a Phase II efficacy trial of Ruxoprubart (NM8074) for Dermatomyositis (DM),...
Synergia Medical Announces Strong Results for nao.vns First-in-Human Study
Synergia Medical’s NAO.VNS™ device, implanted in five patients in Belgium, has met its primary safety endpoint in the AURORA...